AGAbdul Ghani

Abdul Ghani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdul Ghani has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left atrioventricular coupling index in patients undergoing cardiac resynchronization therapy

    by Cheyenne S. L. Chiu, Willem Gerrits, Sophie C. Rier, Philippe C. Wouters, Maarten J. Cramer, Ivo A. C. van der Bilt, Pim van der Harst, Muhammed I. Girgin, Kevin Vernooy, Antonius M. W. van Stipdonk, et al.

    The left atrioventricular coupling index (LACI), defined as the ratio of left atrial (LA) to left ventricular (LV) end-diastolic volumes, serves as a surrogate for atrioventricular coupling. Cardiac resynchronization therapy (CRT) promotes reverse remodeling of both chambers and may enhance atrioventricular coupling, yet the clinical utility of LACI in CRT patients remains unclear. This study evaluated the effect of CRT on LACI and assessed its prognostic value for CRT response. In 123 patients enrolled in the ADVISE-CRT III trial (mean age 66 ± 10 years; 63% male; and 81% with a Class I CRT indication), LACI was measured by echocardiography before and six months after CRT implantation. Multivariable linear and logistic regression analyses were performed to assess the association between LACI and CRT response (≥ 15% LV end-systolic volume reduction), adjusting for potential confounders. Low baseline LACI was independently associated with an 11.2% greater LV end-systolic volume reduction (Quartile 1–2 vs. Quartile 3–4; p = 0.009) and 3.6-fold higher odds of CRT response (p = 0.041). At six months, LACI increased significantly in responders (16.5% to 20.7%; p < 0.001), driven by greater LV versus LA end-diastolic volume reduction. In non-responders, LACI remained stable (20.9% to 20.3%; p = 0.077). LACI was independently associated with CRT response and provided incremental value over individual LA and LV volumetric parameters. While LACI may reflect favorable structural substrate and atrioventricular coupling at baseline, it is not suitable for post-CRT assessment of atrioventricular coupling, as disproportionate LV versus LA remodeling may conceal coupling improvements. Graphical abstract Left atrioventricular coupling index in patients undergoing cardiac resynchronization therapy


  • Top Cited Papers
    Open Access

    Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial

    by Louise R.A. Olde Nordkamp, Jolien A. de Veld, Abdul Ghani, Jürgen Kuschyk, Hendrik Bonnemeier, Kerstin Bode, Lucas V.A. Boersma, Anouk de Weger, Jonas S.S.G. de Jong, Ward P.J. Jansen, et al.

    BACKGROUND: The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) investigated the efficacy and safety of the subcutaneous implantable cardioverter defibrillator (S-ICD) compared with a transvenous ICD (TV-ICD) and showed noninferiority of the S-ICD with regard to the composite end point of device-related complications and inappropriate shocks after 49.1 months. Complications associated with transvenous leads are expected to occur after longer follow-up. The PRAETORIAN-XL trial aims to investigate whether the S-ICD is superior to the TV-ICD with respect to device-related complications at 8-year follow-up. METHODS: The PRAETORIAN trial randomized patients with a class I or IIa indication for ICD therapy without the need for pacing to either S-ICD or TV-ICD among 39 centers in the United States and Europe between March 2011 and January 2017. The follow-up was extended after 49.1 months by an additional 4 years for the PRAETORIAN-XL trial. The primary end point was the composite of all device-related complications. Complications could be related or unrelated to the lead and minor or major, with major complications being those requiring an invasive intervention. End points were analyzed according to the modified intention-to-treat principle using a Fine-Gray subdistribution hazards model to account for competing risks. An as-treated analysis was performed using a Cox proportional hazards model with device type as time-dependent variable. RESULTS: Patients were randomized to S-ICD (n=426) and TV-ICD (n=423). Twenty-one percent of the S-ICD group versus 18% of the TV-ICD group were women. The median age at implantation was 63 (interquartile range, 54–69) years for the S-ICD and 64 (interquartile range, 56–69) years for the TV-ICD. After a median follow-up of 87.5 months, all device-related complications (major and minor combined) were not significantly different in the modified intention-to-treat analysis (subdistribution hazard ratio, 0.73 [95% CI, 0.48–1.12]); P =0.15). However, TV-ICD patients more often had a major complication or lead-related complication ( P =0.03 and P P =0.047). CONCLUSIONS: The PRAETORIAN-XL trial demonstrated that there was no significant difference between the S-ICD and TV-ICD in all device-related complications during long-term follow-up. However, the TV-ICD carries a higher risk of major and lead-related complications compared with S-ICD therapy. The S-ICD should therefore be considered for all patients without a pacing indication who are evaluated for ICD therapy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01296022.


  • Open Access

    Quality of Life in Subcutaneous or Transvenous Implantable Cardioverter-Defibrillator Patients: A Secondary Analysis of the PRAETORIAN Trial

    by Reinoud E. Knops, Jolien A. de Veld, Abdul Ghani, Lucas V.A. Boersma, Juergen Kuschyk, Mikhael F. El Chami, Hendrik Bonnemeier, Elijah R. Behr, Tom F. Brouwer, Stefan Kääb, et al.

    BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) was developed to overcome the risk of lead-related complications associated with the transvenous implantable cardioverter-defibrillator (TV-ICD). In contrast to the TV-ICD, the S-ICD is a completely extrathoracic device. Subsequently, complications differ between these 2 implantable cardioverter-defibrillators, which might impact patient perceptions of the therapies. This prespecified secondary analysis of the PRAETORIAN trial evaluates differences in quality of life. METHODS: The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) randomized patients with an implantable cardioverter-defibrillator indication, without the need for pacing to S-ICD or TV-ICD therapy. Two questionnaires were collected at baseline, discharge, 12 months, and 30 months. The Duke Activity Status Index measures cardiac-specific physical functioning, and the 36-Item Short Form Health Survey measures physical and mental well-being, with the subscales bodily pain and mental health being of interest in this analysis. Mann-Whitney U tests were used to compare study arms, and a mixed model was used to describe the questionnaire outcomes over time. RESULTS: Patients were randomized to S-ICD (n=426) and TV-ICD (n=423). In the S-ICD group, 20% were women versus 19% in the TV-ICD group. The median age was 63 (interquartile range, 54–69) years in the S-ICD group versus 64 (interquartile range, 56–69) years in the TV-ICD group. There were no significant differences in the Duke Activity Status Index and 36-Item Short Form Health Survey subscales for bodily pain and mental health between the groups at any time point. Patients with a shock in the last 90 days had significantly lower scores for social functioning ( P =0.008) and role limitations due to emotional problems ( P =0.001) than patients without a shock, but this effect did not differ between treatment arms. CONCLUSIONS: In a large randomized cohort of patients with an S-ICD or TV-ICD, no difference in overall quality of life was observed. However, implantable cardioverter-defibrillator shocks resulted in a reduction in quality of life, regardless of the device type or appropriateness. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01296022.


  • Open Access

    Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation

    by A. Ghani, P. P. H. M. Delnoy, A. R. Ramdat Misier, J. J. J. Smit, A. Adiyaman, J. P. Ottervanger, A. Elvan

    Background The number of cardiac rhythm device implantations has been growing fast due to expanding indications and ageing of the population. Complications of implantation were rare in the trials. However, these involved small numbers and selected patients. Prospective real-life data are necessary to assess cardiac device implantation procedure-related risks. Objective To determine the incidence and predictors of lead-related re-intervention in a Dutch high-volume teaching hospital. Methods Data from all patients who underwent cardiac rhythm device implantation between January 2010 and December 2011 were collected in a prospective registry. At least 1 year of follow-up regarding re-intervention was available for all patients. Lead-related reasons for re-intervention were categorised into lead dislodgement, malfunctioning or perforation. Results One thousand nine hundred twenty-nine devices including 3909 leads were implanted. In 595 patients (30.8 %) a CRT-D/P was implanted. Lead-related re-intervention was necessary in 86 (4.4 %) patients; it was more common in younger and male patients, and due to either lead dislodgement (66 %), malfunctioning (20 %) or perforation (18 %). Coronary sinus lead dislodgement or malfunctioning was 1.4 %. Right atrial dislodgement (1.9 %, p < 0.001) or ICD lead dislodgement (1.8 %, p = 0.002) was more common than right ventricular dislodgement (0.3 %). The incidence of lead malfunctioning was higher (0.8 %) in ICD leads. An apical position of the right ventricular lead and lateral wall position of the right atrial lead were related to cardiac perforation. Conclusions The incidence of lead-related re-intervention was comparable with the literature. The majority of re-interventions were due to lead dislodgements, particularly with right atrial and ICD leads. Re-intervention due to coronary sinus lead dislodgement was rare.